The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Mexico from a collective perspective

References

• Chugh SS, Havmoeller R, Narayanan K, et al. worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2013;25:837-47
   Google Scholar
• Cubillos L, Haddad A, Mould J, et al. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med 2014;7:441-48
   PubMedGoogle Scholar
• Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-e354
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation Chest 2012;141:e531S-75S
   PubMed Web of Science ®Google Scholar
• Members WG, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics—2010 update a report from the American Heart Association. Circulation 2010;121:e46-e215
   PubMed Web of Science ®Google Scholar
• Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 2011;42:2351-5
   PubMed Web of Science ®Google Scholar
• Mayo N, Wood-Dauphinee S, Ahmed S, et al. Disablement following stroke. Disabil Rehabil 1999;21:258-68
   PubMed Web of Science ®Google Scholar
• Gonzalez-Zuelgaray J. The burden of stroke and atrial fibrillation. ISPOR 3rd Latin American Conference; Mexico City, Mexico: September 2011
   Google Scholar
• Christensen MC, Valiente R, Sampaio Silva G, et al. Acute treatment costs of stroke in Brazil. Neuroepidemiology 2009;32:142-9
   PubMed Web of Science ®Google Scholar
• Evers SMAA, Struijs JN, Ament AJHA, et al. International comparison of stroke cost studies. Stroke J Cereb Circ 2004;35:1209-15
   Web of Science ®Google Scholar
• Alcocer L. Challenges and treatment for stroke prophylaxis in patients with atrial fibrillation in Mexico: a review. Am J Cardiovasc Drugs Drugs Devices Interv 2016;16:171-82
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:2246-80
   Web of Science ®Google Scholar
• Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-92
   PubMed Web of Science ®Google Scholar
• Boulanger L, Kim J, Friedman M, et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 2006;60:258-64
   PubMed Web of Science ®Google Scholar
• Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin. J Med 2003;70:361-71
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106
   PubMed Web of Science ®Google Scholar
• Witt DM, Delate T, Clark NP, et al. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res 2013;132:e124-30
   PubMed Web of Science ®Google Scholar
• Hidalgo-Vega A, Askari E, Vidal R, et al. Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation. BMC Health Serv Res 2014;14:46
   PubMed Web of Science ®Google Scholar
• Walsh C, Murphy A, Kirby A, et al. Retrospective costing of warfarin. Ir Med J 2014;107:133-5
   PubMedGoogle Scholar
• Ali A, Bailey C, Abdelhafiz AH. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis. Age Ageing 2012;41:681-4
   PubMed Web of Science ®Google Scholar
• Schulman S, Anderson DR, Bungard TJ, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 2010;8:2192-200
   PubMed Web of Science ®Google Scholar
• Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF Clinical Trial. J Am Heart Assoc 2013;2:e000067
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Clin Epidemiol 1987;40:373-83
   Google Scholar
• Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation 2003;107:1692-711
   PubMed Web of Science ®Google Scholar
• Chambers S, Chadda S, Plumb JM. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. Int J Lab Hematol 2010;32:427-42
   PubMed Web of Science ®Google Scholar
• Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014;129:1407-14
   PubMed Web of Science ®Google Scholar
• Dolan G, Smith LA, Collins S, et al. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature. Curr Med Res Opin 2008;24:1459-72
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Rost NS, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: effective anticoagulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48. Stroke J Cereb Circ 2014;45:2372-8
   Web of Science ®Google Scholar
• White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239-45
   PubMed Web of Science ®Google Scholar